Dogwood Therapeutics Inc (DWTX) FinancialsDWTXDogwood Therapeutics Inc

Evaluating the bottom line, Dogwood Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -143.45%, provide a clear picture of how effectively DWTX converts its operational activities into shareholder value.

In the context of the broader market, DWTX competes directly with industry leaders such as FRMM and GRCE. With a market capitalization of $44.36M, it holds a leading position in the sector. When comparing efficiency, DWTX's gross margin of N/A stands against FRMM's 29.16% and GRCE's N/A. Such benchmarking helps identify whether Dogwood Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Dogwood Therapeutics has been facing significant financial challenges, with a net income loss of -$11,529,609 in Q2 2026 and a gross profit of $0 in recent quarters, highlighting ongoing profitability issues.